Methods and compositions for cancer treatment
US-2024424094-A1 · Dec 26, 2024 · US
Targeting of bone marrow neovasculature
US9446124B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9446124-B2 |
| Application number | US-201414219145-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 19, 2014 |
| Priority date | Aug 5, 2009 |
| Publication date | Sep 20, 2016 |
| Grant date | Sep 20, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Antibodies which bind an antigen of the bone marrow neovasculature in leukemia patients, for use in treatment and diagnosis of leukemia, in particular the treatment and diagnosis of acute myeloid leukemia (AML).
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating acute myeloid leukemia in an individual in need thereof, said method consisting essentially of administering to said individual a therapeutically effective amount of an antibody that binds an antigen which is differentially expressed in the bone marrow neovasculature in acute myeloid leukemia patients, said antigen being the Extra Domain-A (ED-A) isoform of fibronectin and said antibody having an antigen binding site comprising a VH domain and a VL domain, said VH domain comprising a VH CDR1 of SEQ ID NO:16, a VH CDR2 of SEQ ID NO:17 and a VH CDR3 of SEQ ID NO:18, and said VL domain comprising a VL CDR1 of SEQ ID NO:19, a VL CDR2 of SEQ ID NO:20 and a VL CDR3 of SEQ ID NO:21. 2. The method of claim 1 , wherein the antibody is conjugated to a bioactive molecule, said bioactive molecule being selected from the group consisting of a cytokine, cytotoxic agent, photosensitizer and a therapeutic radioisotope. 3. The method of claim 2 , wherein the antibody is conjugated to the bioactive molecule via a cleavable linker. 4. The method of claim 1 wherein the VH domain is the F8 V5L VH domain of SEQ ID NO:13and the VL domain is the F8 K18R VL domain of SEQ ID NO:15. 5. The method of claim 1 , wherein the antibody is a small immunoprotein (SIP), scFv, or whole IgG molecule. 6. The method of claim 2 , wherein the VH domain is the F8 V5L VH domain of SEQ ID NO:13, and the VL domain is the F8 K18R VL domain of SEQ ID NO:15. 7. The method of claim 3 , wherein the VH domain is the F8 V5L VH domain of SEQ ID NO:13, and the VL domain is the F8 K18R VL domain of SEQ ID NO:15.
Assignees
Inventors
Classifications
- A61K39/39558Primary
against tumor tissues, cells, antigens · CPC title
- C07K16/18Primary
against material from animals or humans · CPC title
from primates, e.g. man · CPC title
CH4 domain · CPC title
Blood cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9446124B2 cover?
- Antibodies which bind an antigen of the bone marrow neovasculature in leukemia patients, for use in treatment and diagnosis of leukemia, in particular the treatment and diagnosis of acute myeloid leukemia (AML).
- Who is the assignee on this patent?
- Philogen Spa, Philochem Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39558. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).